|
MechanismMPXV M1R inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Shanghai Shangyao Kangxinuo Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shanghai Shangyao Kangxinuo Biopharmaceutical Co., Ltd.
100 Deals associated with Shanghai Shangyao Kangxinuo Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Shanghai Shangyao Kangxinuo Biopharmaceutical Co., Ltd.